QUEBEC CITY, May 8 /CNW Telbec/ - Asmacure Ltée announced today that the
company has closed a Series A round of financing of 9 million $US involving
Fonds Bio-Innovation and Innovatech Québec Chaudière-Appalaches from Québec
City, and Domain Associates from Princeton, New Jersey. This investment will
support Asmacure's operations and R & D program through the preclinical and
initial clinical development of its Lead Compound aimed at a new
pharmacological approach for the treatment of asthma.
